Revolutionary drug development for chronic pain treatment.
Immunalgia Therapeutics ha iniciado los estudios clínicos de seguridad en voluntarios sanos.
Immunalgia Therapeutics ha obtenidos fondos del Banco Interamericano de Desarrollo (BID), para continuar con los estudios clínicos de Fase 2/3 en pacientes con dolor crónico.
Dos de los socios fundadores de Immunalgia Theraputics, recibirán el premio anual otorgado por la Asociación Internacional para el Estudio y Tratamiento del Dolor (IASP).
Immunalgia Therapeutics was created in 2019 by three renowned scientist from the National Scientific and Technical Research Council (CONICET) (Argentina) with complementary capabilities that include: a solid background in drug …
Immunalgia Therapeutics is determined to change the future of chronic pain treatment, by using a disruptive technology based on small fractions of synthetic oligonucleotides. These molecules were identified, characterized and …
Immunalgia Therapeutics is proud to announce a significant breakthrough in our mission to transform the treatment of chronic pain conditions. Our lead candidate and first-in-class multitarget drug, IMT-504, has successfully …
The prize given by MERCK-SHARP-DHOME ARGENTINA and THE MINISTRY OF SCIENCE, TECHNOLOGY AND INNOVATION rewards the most talented Start-ups and health technology based companies from Argentina with potential of global …
This is a single-center, open-label, dose-escalating phase I clinical trial in healthy volunteers 18 to 60 years old. This clinical trial is designed to assess the safety, and pharmacokinetics of …
